|  |
| --- |
| [Inflammatory bowel diseases plexus](https://www.crohnscolitisfoundation.org/research/grants-fellowships/ibd-plexus) |
| Funder | [Crohn's and Colitis Foundation of America, Inc. (CCFA)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%221b3913af-a2cb-4004-a635-d1d75de8f0f3%22&sponsorParentId=%221b3913af-a2cb-4004-a635-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
|  - Confirmed / sponsor | Application - required | Proposals are reviewed six times per year and are accepted until all awards are distributed. |

 |
| Eligibility | The lead PI must be an investigator with expertise in a relevant field of research. The PI and any co-PIs must be employed by an institution engaged in health care or health care-related research. Proposals involving multiple institutions are welcome. |
| Abstract | Crohn's and Colitis Foundation of America invites proposals for its Inflammatory bowel diseases plexus opportunity. This provides academic and industry researchers with access to research-ready datasets and biosamples to more rapidly perform activities that promise to speed treatment development, optimise existing therapies through development of biomarkers and diagnostics, and improve health outcomes. Proposals that would utilise IBD Plexus biosamples or data to facilitate efforts in: identification or validation of diagnostics or biomarkers; therapeutic development and optimisation; disease management; or disease prevention. |
| Website | <https://www.crohnscolitisfoundation.org/research/grants-fellowships/ibd-plexus> |
| [ECCO-IBUS intestinal ultrasound research grant](https://www.ecco-ibd.eu/science/fellowships-and-grants.html) |
| Funder | [European Crohn's and Colitis Organisation](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22aee75c87-4a03-4696-a8bc-d1d75de8f0f3%22&sponsorParentId=%22aee75c87-4a03-4696-a8bc-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 31 Oct 2023 - Anticipated / sponsor | Application - required |  |

 |
| Amount | **Upper: €20,000 EUR Lower: €20,000 EUR**A clinical research fund of 20,000 EUR will be awarded to the successful investigator for one year. |
| Eligibility | Applicants must be members of IBUS at the time of application and should be established within clinical units with expertise in inflammatory bowel disease, with established expertise in the performance of intestinal ultrasound and routine access to an ultrasound machine. |
| Abstract | The European Crohn's and Colitis Organisation, in collaboration with the International Bowel Ultrasound Group, invites applications for its intestinal ultrasound research grant. This supports research into the utility of intestinal ultrasounds used in the assessment of patients with inflammatory bowel disease. Applicants must be members of IBUS at the time of application and should be established within clinical units with expertise in inflammatory bowel disease, with established expertise in the performance of intestinal ultrasound and routine access to an ultrasound machine.The grant is worth €20,000. |
| Website | <https://www.ecco-ibd.eu/science/fellowships-and-grants.html> |
| [Seed Grants](https://cms.aesnet.org/research-funding/funding/established/seed-grants) |
| Funder | [American Epilepsy Society (AES)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22b54bf3fb-6b18-4a7c-83d4-d1d75de8f0f3%22&sponsorParentId=%22b54bf3fb-6b18-4a7c-83d4-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 11 Jan 2024 - Anticipated / sponsor | Full Proposal - required |  |

 |
| Deadline Note | Opens in September. |
| Amount | **Upper: $20,000 USD**Seed grants may provide up to $20,000 for one year for direct costs only. They may not be renewed. |
| Eligibility | Applications may come from individual investigators or from two or more collaborating investigators. The primary investigator (PI) or at least one of the primary investigators in a multiple-PI seed grant must be: 1) an AES member; 2) an established investigator with at least an Associate Professor or equivalent level appointment; and 3) an epilepsy focused academic investigator. An assistant professor(s) may serve as a collaborator or Co-PI on the project provided that the application is submitted by the established professor and the award is contracted at least in part for use by the established professor. |
| Abstract | AES Seed Grants offer funds to help enable established investigators to pursue new and innovative lines of research, collaborations, and/or research methods.**What types of research are competitive?** Specific fields of research are competitive for funding from our partners, some of whom have offered to fund a grant in full. If a proposal aligns with the priorities of a partner who will fund in full, some eligibility requirements may be waived and the proposals will compete for a separate pool of funding. |
| Website | <https://cms.aesnet.org/research-funding/funding/established/seed-grants> |

|  |
| --- |
| [Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)](https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-814.html) |
| Funder | [National Heart, Lung, and Blood Institute (NHLBI)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22db26bb37-5a1b-42d8-b9b9-d1d75de8f0f3%22&sponsorParentId=%22db26bb37-5a1b-42d8-b9b9-d1d75de8f0f3%22)[National Institutes of Health (NIH)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22e30bfadb-8101-48be-986f-d1d75de8f0f3%22&sponsorParentId=%22e30bfadb-8101-48be-986f-d1d75de8f0f3%22)[United States Department of Health and Human Services (HHS)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%228a08ea98-db86-4acb-8b95-d1d75de8f0f3%22&sponsorParentId=%228a08ea98-db86-4acb-8b95-d1d75de8f0f3%22)Funder's opportunity ID: NOT-HL-20-814 |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 05 Jul 2024 - Confirmed / sponsor | Application - required |  |

 |
| Deadline Note | Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice. This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through July 5, 2024 of reissued FOAs.PA-20-183PA-20-185 |
| Abstract | The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.This NOSI encourages, but is not limited to, research applications in the following areas:- What are the host resilience factors (e.g., epigenetics, preexisting structural lung/heart/vascular or immune deficiencies, the severity of the lung inflammatory response) that influence resolution and recovery from ARDS/ALI?- What are the reparative or regenerative mechanisms that contribute to the resolution of lung injury and a return to a healthy host state?- What are the underlying host-response mechanisms that contribute to the disparity of resilience to ARDS/ALI in different race/ethnic groups and different age populations?- What are the underlying host-response mechanisms that determine the outcomes in patients with COVID-19 related ARDS?- What is the molecular mechanism underpinning the effect of metabolic changes and lifestyle on host resilience determining the resolution and recovery in ARDS?- Development of quantitative cell/organ/systems models and measures to identify resilience mechanisms involving inflammation resolution pathways in ARDS. |
| Website | <https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-814.html> |
| [Alzheimer’s Association World Wide FINGERS Network Funding Program (ALZ WW-FNFP)](https://www.alz.org/research/for_researchers/grants/types-of-grants/alzheimers-association-world-wide-fingers-network) |
| Funder | [Alzheimer's Association (ALZ)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%229f5d628f-7e99-4701-a66e-d1d75de8f0f3%22&sponsorParentId=%229f5d628f-7e99-4701-a66e-d1d75de8f0f3%22) |
| Amount | **Upper: $1,000,000 USD**The maximum grant amount is up to $1,000,000 (USD) and the project duration is up to 3 years with no minimum timeframe. No indirect costs are allowed on this award. |
| Eligibility | The ALZ WW-FNFP is open to both U.S. and international researchers in the WW-FINGERS Network, . |
| Abstract | The World Wide FINGERS (WW-FINGERS) Network launched in 2017 as the first global network of multidomain lifestyle intervention trials for dementia risk reduction and ultimately prevention. Studies that participate in the WW-FINGERS network aim to apply, test and optimize the FINGER-like model to reduce risk across the spectrum of cognitive decline in different geographical, cultural and economic settings in individuals at greater risk as they age. To support the expansion and opportunity for advancing this research, the Alzheimer’s Association is launching a pilot funding program for WW-FINGERS Network projects. The ALZ WW-FNFP will provide initial/startup funding and/or opportunities for ongoing studies to initiate WW-FINGERS like studies, to expand these studies or to add/leverage unique opportunities that enhance the study. This will be a competitive funding program and all submissions will be reviewed. |
| Website | <https://www.alz.org/research/for_researchers/grants/types-of-grants/alzheimers-association-world-wide-fingers-network> |

|  |
| --- |
| [Collaborative Advancement of Cures for T1D](https://grantcenter.jdrf.org/rfa/collaborative-advancement-of-cures-for-t1d/) |
| Funder | [JDRF](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%223aa09976-02e4-458f-bd86-d1d75de8f0f3%22&sponsorParentId=%223aa09976-02e4-458f-bd86-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 08 Dec 2023 - Anticipated / sponsor | Letter of Intent - required |  |
| 13 Feb 2024 - Anticipated / sponsor | Full Proposal - required |  |

 |
| Amount | **Upper: $2,250,000 USD**Each partnership may request up to $500,000 per year for those with two partners, or up to $750,000 for three or more partners, for up to 3 years. |
| Eligibility | * JDRF welcomes Letters of Intent (LOIs) from established and/or new collaborative teams of investigators, organizations, and companies with the demonstrated expertise to carry out the proposed research.
* Teams of investigators should identify an investigator and institution to serve as the lead applicant, team coordinator and principal investigator of the JDRF application.
* Applications may be submitted by domestic and foreign non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, industry, units of state and local governments, and eligible agencies of the federal government.
* Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.
* There are no citizenship requirements for this program. To assure continued excellence and diversity among applicants and awardees, JDRF welcomes applications from all qualified individuals and encourages applications from persons with disabilities, women, and members of minority groups underrepresented in the sciences.
* JDRF’s standard Terms and Conditions will apply to all non-industry grants. Please review them in advance to ensure your collaboration will be able to comply. Contact your JDRF Program Contact with any questions
 |
| Abstract | The goal of this funding opportunity is to accelerate the development of therapies to prevent, slow, halt or reverse the progression of Type 1 Diabetes (T1D) and/or cure established T1D through the advancement of high-impact research carried out by coordinated, multidisciplinary teams. JDRF, the world’s leading non-profit organization with the mission to cure T1D, aspires to accelerate the development of therapies to prevent, slow, halt or reverse disease progression and provide insulin independence to all those at risk or affected by T1D. Major advancement continues to be made in therapies that protect beta cell survival and function, disrupt the autoimmune attack on beta cells, and provide insulin and restore glycemic control through the use of beta cell transplantation. JDRF seeks to rapidly expand upon and translate these approaches to clinical trials to benefit patients at all stages of disease. Achieving this goal and addressing major advancement of therapies will require expanded resources and broad multidisciplinary expertise, likely more than can be achieved in a single grant or by individual laboratories. |
| Website | <https://grantcenter.jdrf.org/rfa/collaborative-advancement-of-cures-for-t1d/> |

|  |
| --- |
| [Alzheimer's Disease Research (ADR): Standard Awards](https://www.brightfocus.org/grants/types-grants) |
| Funder | [BrightFocus Foundation](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%220d01a866-8243-474c-a3cd-d1d75de8f0f3%22&sponsorParentId=%220d01a866-8243-474c-a3cd-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 01 Nov 2023 - Anticipated / sponsor | Application - required | 5:00PM EST |

 |
| Amount | **Upper: $300,000 USD**Award Amount: $300,000Duration: 3 years |
| Eligibility | BrightFocus will fund grants for research at non-profit organizations or institutions only. Each Grantee Institution must submit evidence of its tax-exempt status to BrightFocus prior to the distribution of any Grant including but not limited to, a tax determination from the Internal Revenue Service. For foreign institutions: Each Grantee Institution must submit evidence of its tax-exempt status to BrightFocus prior to the distribution of any Grant, including but not limited to, a determination of tax-exempt or nonprofit status from their home country of origin.BrightFocus provides research funds for U.S. domestic as well as international researchers.The Principal Investigator (PI) position on BrightFocus Standard Awards are open to tenure- and non-tenure track investigators of any career stage who are appropriately trained to lead an independent research study, and are permitted by their organizations to manage grants and supervise key personnel. Applicants should have completed their formal post-doctoral mentored research training, and must be the intellectual and creative leads for the proposed projects. Postdoctoral Fellows may serve as PI for Alzheimer's Disease Research (ADR) Postdoctoral Fellowships only. |
| Abstract | The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies. |
| Website | <https://www.brightfocus.org/grants/types-grants> |

|  |
| --- |
| [Notice of Special Interest (NOSI): Addressing Evidence Gaps in Screening](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-179.html) |
| Funder | [National Institutes of Health (NIH)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22e30bfadb-8101-48be-986f-d1d75de8f0f3%22&sponsorParentId=%22e30bfadb-8101-48be-986f-d1d75de8f0f3%22)[United States Department of Health and Human Services (HHS)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%228a08ea98-db86-4acb-8b95-d1d75de8f0f3%22&sponsorParentId=%228a08ea98-db86-4acb-8b95-d1d75de8f0f3%22)Funder's opportunity ID: NOT-OD-22-179 |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 08 May 2025 - Confirmed / sponsor | Application - required |  |

 |
| Deadline Note | This NOSI applies to due dates on or after October 4, 2022, and subsequent receipt dates through May 8, 2025. You may submit applications for this initiative using any of the twenty-nine funding opportunity announcements (FOAs) listed on the website above, or any reissues of these announcement through the expiration date of this notice. |
| Abstract | The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. This NOSI encourages the development and use of innovative and rigorous methods and approaches to close high priority evidence gaps to elevate screening services to a level suitable for a definitive grade or recommendation. The specific research interests of participating NIH ICs are detailed within. This NOSI encourages translational research aimed at filling identified knowledge gaps to expand the evidence base for evaluating the balance of benefits and harms for proposed preventive screenings. This includes efficacy, effectiveness, mechanistic, and longitudinal studies, cost effectiveness analyses, as well as research on novel methods, measurements, study designs, analyses, theoretical frameworks, and tools that can generate the research needed to close screening-related evidence gaps. This also includes conceptualizing and validating measures for novel health outcomes to capture the impact of screening, encompassing not just reductions in disease and disability, but also effects on quality of life and subjective well-being. Applicants interested in research involving multilevel interventions to improve the uptake of recommended screening services and/or address barriers to screening are directed to the companion NOSI (NOT-OD-22-178). |
| Website | <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-179.html> |

|  |
| --- |
| [Research grant](http://www.fibrosicisticaricerca.it/area-ricercatori/) |
| Funder | [Fondazione per la Ricerca Sulla Fibrosi Cistica (FFC) | Italian Cystic Fibrosis Research Foundation](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22dbd14e2d-7239-43a0-a9e9-d1d75de8f0f3%22&sponsorParentId=%22dbd14e2d-7239-43a0-a9e9-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 15 Feb 2024 - Confirmed / sponsor | Application - required |  |

 |
| Amount | **Upper: €130,000 EUR** |
| Eligibility | Scientists with proven scientific independence and at least three experimental or clinical papers published in the last five years may apply. PIs must have a permanent position and reside in Italy. If PIs and multicentre project co-ordinators live and work in another European country, at least one partner in the project must be resident and work in Italy. |
| Abstract | The Italian Cystic Fibrosis Research Foundation invites applications for its research grant. This supports research projects aiming to improve the health status of cystic fibrosis patients. Research projects dealing with either clinical studies or pre-clinical studies exploiting animal models of CF are strongly encouraged. Priority areas include:•innovative therapies to correct defective CFTR or to compensate for its deficient function;•identification and validation of new and appropriate in vivo and ex vivo assays to predict and monitor the potential efficacy of new therapies finalised to correct the CFTR defect;•airway infection in CF - development of innovative diagnostic and antimicrobial strategies with special indication for the rapid and accurate diagnosis of infections and the treatment of difficult-to-treat microorganisms;•inflammation in CF - innovative strategies to contain the inflammation-based pathology;•clinical applications and epidemiological studies.Scientists with proven scientific independence and at least three experimental or clinical papers published in the last five years may apply. PIs must have a permanent position. If PIs and multicentre project co-ordinators live and work in another European country, at least one partner in the project must be resident and work in Italy.Grants are worth up to €130,000 for two-year projects or €70,000 for one year. |
| Website | <http://www.fibrosicisticaricerca.it/area-ricercatori/> |
| [Research grants](https://www.gbs-cidp.org/research/) |
| Funder | [GBS CIDP Foundation International](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%223a065f99-8da1-4180-a11b-d1d75de8f0f3%22&sponsorParentId=%223a065f99-8da1-4180-a11b-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 01 Nov 2023 - Anticipated / sponsor | Letter of Intent - required |  |
| 31 Jan 2024 - Anticipated / sponsor | Application - required |  |

 |
| Amount | **Upper: $60,000 USD**Multiple grants worth up to USD 60,000 over one year are available. |
| Eligibility | The foundation encourages all interested parties to submit applications, including international applicants. |
| Abstract | GBS/CIDP Foundation International invites letters of intent for its research grants. These support researchers who are committed to learning more about Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy and variants. |
| Website | <https://www.gbs-cidp.org/research/> |

|  |
| --- |
| [Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-023.html) |
| Funder | [National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22c0a89b19-acd2-4382-9038-d1d75de8f0f3%22&sponsorParentId=%22c0a89b19-acd2-4382-9038-d1d75de8f0f3%22)[National Institutes of Health (NIH)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22e30bfadb-8101-48be-986f-d1d75de8f0f3%22&sponsorParentId=%22e30bfadb-8101-48be-986f-d1d75de8f0f3%22)[United States Department of Health and Human Services (HHS)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%228a08ea98-db86-4acb-8b95-d1d75de8f0f3%22&sponsorParentId=%228a08ea98-db86-4acb-8b95-d1d75de8f0f3%22)Funder's opportunity ID: RFA-DK-22-023 |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 08 Nov 2023 - Confirmed / sponsor | Application - required | New, resubmission |

 |
| Deadline Note | Optional Letter of Intent due 30 days before application due date All applications are due by 5:00 PM local time of applicant organization. |
| Amount | NIDDK intends to commit $3,300,000 in FY 2024 to fund up to 7 awards. Application budgets are limited to $300,000 direct costs per year. The maximum project period is 4 years for applications submitted to the first due date (March 09, 2023), and 3 years for applications submitted to the second due date (November 08, 2023). |
| Abstract | The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified over 250 susceptibility loci for inflammatory bowel disease (IBD). The IBDGC was renewed recently with a continued mission to characterize the genetic architecture of IBD phenotypes in diverse populations and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology and clinical course. However, current resources permit functional investigation of only a limited number of loci, genes and physiological domains, while the biological mechanisms underlying most of the identified IBD risk loci remain unknown. The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of IBD susceptibility loci, causal variants and effector genes, and IBD-related phenotypes and physiological domains under investigation via Ancillary Studies utilizing the extensive resources, including subjects, samples and datasets, established by the IBDGC. Proposed Ancillary Studies should focus on causal variant identification and/or functional characterization of effector genes within IBD risk loci and must not duplicate studies that are either ongoing or already completed by the IBDGC. |
| Website | <https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-023.html> |

|  |
| --- |
| [Distinguished innovator grant](https://novonordiskfonden.dk/da/grants/distinguished-innovator-grant-fall-2022/) |
| Funder | [Novo Nordisk Fonden | Novo Nordisk Foundation](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22eca3bd7f-50a6-4112-8b11-d1d75de8f0f3%22&sponsorParentId=%22eca3bd7f-50a6-4112-8b11-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 09 Mar 2024 - Anticipated / sponsor | Application - required | Applications are due between 9 Janduary and 2pm 9 March 2022.  |

 |
| Amount | **Upper: 6,000,000 kr. DKK** |
| Abstract | The Novo Nordisk Foundation invites applications for its distinguished innovator grant. This enables a researcher in the life sciences to explore the commercial potential of a discovery while remaining embedded in academia. The grant offers the resources to test and mature discoveries throughout a full innovation lifecycle which may lead to the development of new medical treatments or health technologies, disease prevention, diagnostic methods, industrial biotech, or devices to benefit people and society. Applicants may be faculty members or senior researchers employed at research institutions or hospitals and clinics in Denmark, Sweden, Norway or Finland. They may also be based within the pharma, industrial biotech or medtech industries. Applicants must hold a research position and have a proven track record within innovation, such as previous experience of academic innovation projects or experience of establishing spin-outs from academia. The grant must be administrated by a non-profit organisation. The total budget is worth DKK 84 million. Grants are worth up to DKK 6m over three years. |
| Website | <https://novonordiskfonden.dk/da/grants/distinguished-innovator-grant-fall-2022/> |

|  |
| --- |
| [The Mallinckrodt Uveitis Research Fellowship](https://www.arvo.org/arvo-foundation/what-we-fund/awards-grants-and-fellowships/mallinckrodt-uveitis-research-fellowship/) |
| Funder | [ARVO Foundation for Eye Research (AFER)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%227b8f7d9b-0559-4d8e-a3f6-d1d75de8f0f3%22&sponsorParentId=%227b8f7d9b-0559-4d8e-a3f6-d1d75de8f0f3%22)[Association for Research in Vision and Ophthalmology (ARVO)](https://pivot.proquest.com/funding/results?quick_search=true&sponsorId=%22795f4be6-ae4c-4606-ab20-d1d75de8f0f3%22&sponsorParentId=%22795f4be6-ae4c-4606-ab20-d1d75de8f0f3%22) |
| Upcoming deadlines |

|  |  |  |
| --- | --- | --- |
| **Date** | **What's due** | **Notes** |
| 01 Sep 2023 - Anticipated / sponsor | Application - required | Opens July 1st. |

 |
| Amount | **$45,000 USD**Fellowship is for one year. |
| Abstract | The intent of the award is to provide investigators who are early in their careers with an opportunity to explore novel and innovative ideas and to promote the generation of promising preliminary results that may be leveraged to catalyze success in both earning additional, longer-term funding support as well as the authorship of impactful publications and the stimulation of further insights and advances in the ocular inflammation space. |
| Website | <https://www.arvo.org/arvo-foundation/what-we-fund/awards-grants-and-fellowships/mallinckrodt-uveitis-research-fellowship/> |

# Open Call for project funding 2024 for the Nordic Working Group for Chemicals, Environment, and Health (NKE)

Deadline for applications is 9.6.2023 - 23:59

**Relaterade organisationer**

[Nordic Working Group for Chemicals, Environment, and Health (NKE)](https://www.norden.org/en/organisation/nordic-working-group-chemicals-environment-and-health-nke)

Open to: Danmark, Sverige, Finland, Färöarna, Island, Åland, Norge, Grönland

NKE is working towards to help minimise the negative health and environmental effects of chemicals in products, emissions and waste. NKE covers a wide area and co-operation on chemicals is a big challenge. Over the years, NKE has built and expanded networks of experts from national agencies in the Nordic countries. NKE has also set up sub-groups (project groups) as per the targets set for the various areas.

Nordic co-operation has often taken the form of exerting influence on EU regulations but also covers other aspects of international work, e.g. conventions, the Arctic environment, test methods and OECD work on chemicals, which also forms the foundations for EU regulation. NKE believes that the networks have the best prerequisite for coming up with new and current questions how Nordic work can address the critical issues with chemicals in the Nordic countries, the EU, and globally. We welcome new ideas and encourage forward way of thinking: What knowledge do we lack today and what do we need to acquire knowledge of?

NKE focuses on goals set in the Programme for Nordic Co-operation on the Environment and Climate 2019–2024 and Our Vision 2030 and prioritises projects according to these goals.

The applications will be assessed based on

• their alignment of the Programme for Nordic Cooperation and Vision 2030 goals

• the relevance for NKE work and Nordic utility

• quality of the project description

• communication plan for the results generated.

You can apply by sending application to NKE coordinator **miia.hakkinen@tukes.fi**

Website: <https://www.norden.org/sv/node/80106>